Effect of Menthol on ENDS Users' Addiction and Exposure

Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age21-35
SponsorFlorida International University

About this trial

The use of electronic nicotine delivery systems (ENDS; e-cigarettes) has reached epidemic levels among young people in the United States (US). ENDS heat and vaporize a nicotine-containing liquid to produce an inhalable aerosol mist. While generally considered less harmful than combustible cigarettes, ENDS use exposes users to dependence-producing nicotine and respiratory and cardiovascular toxicants such as aldehydes. Flavor is a major factor in getting young people to use ENDS, thus limiting flavors to menthol and tobacco for prefilled cartridge ENDS "pod mods" was the first major action taken by the FDA to reduce the spread of ENDS among young people. Menthol flavor, however, can present a potential risk given its increasing popularity among young people in the US, and its puffing and nicotine-enhancing properties. Yet, the extent of menthol's ability to affect users' experience and puffing patterns, and how these affect dependence, exposure to toxicants, and clinical outcomes continue to be understudied. Such evidence will be critical to the FDA's ability to set further regulatory standards to reduce ENDS potential harm. The investigators will conduct a 2x2 (pre-post x menthol vs. tobacco flavor) crossover clinical lab study. The investigator will recruit current/past month ENDS users (n=250, 21-35 yrs), who will attend two sessions and use their ENDS once with menthol and once with tobacco flavors. The proposed studies will answer two key regulatory questions consistent with FDA's focus on the role of flavor in tobacco products' addiction and toxicity; 1) compared to tobacco flavor, does menthol carry additional risk by enhancing puffing, abuse liability, and toxicant exposure in ENDS users, and; 2) is this effect more pronounced among high dependence compared to other users. Other outcomes such as harm perception, satisfaction, clinical responses, intention to use or quit, and group comparisons such as according to race, and sex will allow the FDA a comprehensive assessment of the pros and cons of regulating mentholated ENDS for different segments of the society. Such evidence will help advance FDA regulatory policies with the potential to reduce ENDS harm.

Eligibility criteria

This trial accepts healthy volunteers

Qualifiers

Generally healthy individuals (determined by physical examination).

Age of 21-35 years.

Is willing to provide informed consent.

Is willing to attend the lab as required by the study protocol.

Disqualifiers

Report smoking cigarettes regularly (> 5 cigarettes/month in the past year).

Report regular use of any other tobacco/nicotine product (e.g., e-cig, pipes, cigars) in the past year.

Women who are breast-feeding or test positive for pregnancy (by urinalysis at screening).

Individuals with self-reported history of chronic disease or psychiatric conditions.

Trial design

Design model

Crossover

Treatments tested in this trial

  • Menthol-flavored e-cigarette

    Other intervention

    All participants will complete a lab visit where they will use menthol-flavored e-cigarette ad libitum for up to 60 minutes.

  • Tobacco-flavored e-cigarette

    Other intervention

    All participants will complete a lab visit where they will use tobacco-flavored e-cigarette ad libitum for up to 60 minutes.

Treatment groups

250 Participants
are divided into 2 treatment groups
Group A: Menthol-flavored e-cigaretteExperimental treatment 1 intervention
Group B: Tobacco-flavored e-cigaretteExperimental treatment 1 intervention

Trial outcomes

Primary outcomes

1

Plasma nicotine

Change in plasma nicotine level

Time frame
During the 2 participant visits. Blood will be taken 2 times in each e-cigarette use session: before and after an approximately 60 minutes ad lib use period

Secondary outcomes

1

Minnesota Nicotine Withdrawal Scale

This scale is used to assess the extent to which product use reduces tobacco abstinence. symptoms, and consists of 11 items scored 0 - 100. These items are presented as Visual Analog Scale with item (measure) centered above a horizontal line anchored on the left with not at all and on the right with extremely.

Time frame
During participants' 2 study visits. Questionnaire will be administered 2 times in each e-cigarette use session: before and after an approximately 60 minutes ad lib use period
2

Tiffany-Drobes Questionnaire of Smoking Urges

This scale is used to assess the extent to which product use reduces tobacco abstinence symptoms, and consists of 10 items that are scored 0 - 7. Rated on a 7-point Likert scale ranging from 0 (strongly disagree) to 6 (strongly agree).

Time frame
During participants' 2 study visits. Questionnaire will be administered 2 times in each e-cigarette use session: before and after an approximately 60 minutes ad lib use period
3

Carbon monoxide levels

Change in carbon monoxide levels (in parts per million).

Time frame
During participants' 2 study visits. Carbon monoxide levels will be measured 2 times in each e-cigarette use session: before and after an approximately 60 minutes ad lib use period
4

Harm perception

This scale will assess harm perception and measure perceptions of e-cigarette. relative risk compared to cigarettes. The scale will be scored on a 7-point scale ranging from 1 (not at all harmful), to 7 (extremely harmful).

Time frame
During participants' 2 study visits. Questionnaire will be administered after each of the 2 e-cigarette use sessions. Each session is approximately 60 minutes ad lib use period

Other outcomes

1

Heart rate

Change in heart rate, measured in beats per minute.

Time frame
During participants' 2 study visits. Heat rate will be measured from baseline continuously throughout each approximately 60 minutes session
2

Systolic blood pressure

Change in systolic blood pressure, measured in mm/hg.

Time frame
During participants' 2 study visits. Systolic blood pressure will be measured from baseline continuously throughout each approximately 60 minutes session
3

Diastolic blood pressure

Change in diastolic blood pressure, measured in mm/hg.

Time frame
During participants' 2 study visits. Diastolic blood pressure will be measured from baseline continuously throughout each approximately 60 minutes session

Sponsors and contacts

Click on the lead sponsor to view all of their trials.